{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:34:44Z","timestamp":1790501684262,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12264-018-0293-8","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:38:59Z","timestamp":1538095139000},"page":"325-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Folate\/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina"],"prefix":"10.1007","volume":"35","author":[{"given":"Jing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhou","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"293_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1468-1331.2006.01605.x","volume":"14","author":"G Waldemar","year":"2007","unstructured":"Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer\u2019s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007, 14: e1\u201326.","journal-title":"Eur J Neurol"},{"key":"293_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12264-017-0193-3","volume":"33","author":"QH Wang","year":"2017","unstructured":"Wang QH, Wang X, Bu XL, Lian Y, Xiang Y, Luo HB, et al. Comorbidity burden of dementia: a hospital-based retrospective study from 2003 to 2012 in seven cities in china. Neurosci Bull 2017, 33: 703\u2013710.","journal-title":"Neurosci Bull"},{"key":"293_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neuron.2006.09.016","volume":"52","author":"J Hardy","year":"2006","unstructured":"Hardy J. A hundred years of Alzheimer\u2019s disease research. Neuron 2006, 52: 3\u201313.","journal-title":"Neuron"},{"key":"293_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jnutbio.2018.02.001","volume":"55","author":"D Mendes","year":"2018","unstructured":"Mendes D, Oliveira MM, Moreira PI, Coutinho J, Nunes FM, Pereira DM, et al. Beneficial effects of white wine polyphenols-enriched diet on Alzheimer\u2019s disease-like pathology. J Nutr Biochem 2018, 55: 165\u2013177.","journal-title":"J Nutr Biochem"},{"key":"293_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-018-0249-z","author":"BL Sun","year":"2018","unstructured":"Sun BL, Li WW, Zhu C, Jin WS, Zeng F, Liu YH, et al. Clinical research on Alzheimer\u2019s disease: progress and perspectives. Neurosci Bull 2018. \n                    https:\/\/doi.org\/10.1007\/s12264-018-0249-z\n                    \n                  .","journal-title":"Neurosci Bull"},{"key":"293_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awp068","volume":"132","author":"NK Archibald","year":"2009","unstructured":"Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson\u2019s disease. Brain 2009, 132: 1128\u20131145.","journal-title":"Brain"},{"key":"293_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/brain\/awq133","volume":"133","author":"PA Calabresi","year":"2010","unstructured":"Calabresi PA, Balcer LJ, Frohman EM. Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain 2010, 133: 1575\u20131577.","journal-title":"Brain"},{"key":"293_CR8","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1161\/STROKEAHA.113.001741","volume":"44","author":"YT Ong","year":"2013","unstructured":"Ong YT, De Silva DA, Cheung CY, Chang HM, Chen CP, Wong MC, et al. Microvascular structure and network in the retina of patients with ischemic stroke. Stroke 2013, 44: 2121\u20132127.","journal-title":"Stroke"},{"issue":"Suppl 1","key":"293_CR9","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.neuroimage.2010.06.020","volume":"54","author":"M Koronyo-Hamaoui","year":"2011","unstructured":"Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer\u2019s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage\u00a02011, 54 Suppl 1: S204\u2013217.","journal-title":"Neuroimage"},{"key":"293_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ana.24548","volume":"79","author":"C Morgia La","year":"2016","unstructured":"La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol 2016, 79: 90\u2013109.","journal-title":"Ann Neurol"},{"key":"293_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00401-016-1613-6","volume":"132","author":"NJ Hart","year":"2016","unstructured":"Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer\u2019s: exploring disease in the retina. Acta Neuropathol 2016, 132: 767\u2013787.","journal-title":"Acta Neuropathol"},{"key":"293_CR12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMoa011613","volume":"346","author":"S Seshadri","year":"2002","unstructured":"Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D\u2019Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease. N Engl J Med 2002, 346: 476\u2013483.","journal-title":"N Engl J Med"},{"key":"293_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/archneur.55.11.1449","volume":"55","author":"R Clarke","year":"1998","unstructured":"Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998, 55: 1449\u20131455.","journal-title":"Arch Neurol"},{"key":"293_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0b013e3181f88162","volume":"75","author":"B Hooshmand","year":"2010","unstructured":"Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010, 75: 1408\u20131414.","journal-title":"Neurology"},{"key":"293_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ajcn\/82.3.636","volume":"82","author":"G Ravaglia","year":"2005","unstructured":"Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005, 82: 636\u2013643.","journal-title":"Am J Clin Nutr"},{"key":"293_CR16","first-page":"7","volume":"8","author":"AL Miller","year":"2003","unstructured":"Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev 2003, 8: 7\u201319.","journal-title":"Altern Med Rev"},{"key":"293_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jnr.10416","volume":"70","author":"PI Ho","year":"2002","unstructured":"Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002, 70: 694\u2013702.","journal-title":"J Neurosci Res"},{"key":"293_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2005-06-2506","volume":"107","author":"AF Kamath","year":"2006","unstructured":"Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 2006, 107: 591\u2013593.","journal-title":"Blood"},{"key":"293_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nbd.2006.01.005","volume":"22","author":"J Pacheco-Quinto","year":"2006","unstructured":"Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer\u2019s mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 2006, 22: 651\u2013656.","journal-title":"Neurobiol Dis"},{"key":"293_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2353\/ajpath.2009.081036","volume":"174","author":"CE Zhang","year":"2009","unstructured":"Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Liu GP, et al. Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009, 174: 1481\u20131491.","journal-title":"Am J Pathol"},{"key":"293_CR21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.neurobiolaging.2007.04.015","volume":"29","author":"CE Zhang","year":"2008","unstructured":"Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 2008, 29: 1654\u20131665.","journal-title":"Neurobiol Aging"},{"key":"293_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJMoa011364","volume":"345","author":"G Schnyder","year":"2001","unstructured":"Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345: 1593\u20131600.","journal-title":"N Engl J Med"},{"key":"293_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0166-2236(03)00032-8","volume":"26","author":"MP Mattson","year":"2003","unstructured":"Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003, 26: 137\u2013146.","journal-title":"Trends Neurosci"},{"key":"293_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0735-1097(03)00629-6","volume":"42","author":"K Sasaki","year":"2003","unstructured":"Sasaki K, Duan J, Murohara T, Ikeda H, Shintani S, Shimada T, et al. Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol 2003, 42: 364\u2013372.","journal-title":"J Am Coll Cardiol"},{"key":"293_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/jop.2010.0123","volume":"27","author":"SK Gupta","year":"2011","unstructured":"Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther 2011, 27: 123\u2013130.","journal-title":"J Ocul Pharmacol Ther"},{"key":"293_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9: 671\u2013675.","journal-title":"Nat Methods"},{"key":"293_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1006\/neur.1995.0002","volume":"4","author":"JP Brion","year":"1995","unstructured":"Brion JP, Couck AM, Conreur JL. Calcineurin (phosphatase 2B) is present in neurons containing neurofibrillary tangles and in a subset of senile plaques in Alzheimer\u2019s disease. Neurodegeneration 1995, 4: 13\u201321.","journal-title":"Neurodegeneration"},{"key":"293_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0304-3940(97)00230-9","volume":"226","author":"L Minthon","year":"1997","unstructured":"Minthon L, Hesse C, Sjogren M, Englund E, Gustafson L, Blennow K. The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci Lett 1997, 226: 65\u201367.","journal-title":"Neurosci Lett"},{"key":"293_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s004010051040","volume":"97","author":"M Takahashi","year":"1999","unstructured":"Takahashi M, Tsujioka Y, Yamada T, Tsuboi Y, Okada H, Yamamoto T, et al. Glycosylation of microtubule-associated protein tau in Alzheimer\u2019s disease brain. Acta Neuropathol 1999, 97: 635\u2013641.","journal-title":"Acta Neuropathol"},{"key":"293_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0896-6273(93)90279-Z","volume":"11","author":"J Biernat","year":"1993","unstructured":"Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11: 153\u2013163.","journal-title":"Neuron"},{"key":"293_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0006-8993(90)90765-4","volume":"531","author":"IJ Vincent","year":"1990","unstructured":"Vincent IJ, Davies P. Phosphorylation characteristics of the A68 protein in Alzheimer\u2019s disease. Brain Res 1990, 531: 127\u2013135.","journal-title":"Brain Res"},{"key":"293_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pneurobio.2008.03.002","volume":"85","author":"JZ Wang","year":"2008","unstructured":"Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008, 85: 148\u2013175.","journal-title":"Prog Neurobiol"},{"key":"293_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neuint.2013.01.014","volume":"62","author":"Y Liu","year":"2013","unstructured":"Liu Y, Su Y, Wang J, Sun S, Wang T, Qiao X, et al. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int 2013, 62: 458\u2013467.","journal-title":"Neurochem Int"},{"key":"293_CR34","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awu213","volume":"137","author":"L Collin","year":"2014","unstructured":"Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau\/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer\u2019s disease. Brain 2014, 137: 2834\u20132846.","journal-title":"Brain"},{"key":"293_CR35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10: 698\u2013712.","journal-title":"Nat Rev Drug Discov"},{"key":"293_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","volume":"88","author":"C Reitz","year":"2014","unstructured":"Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014, 88: 640\u2013651.","journal-title":"Biochem Pharmacol"},{"key":"293_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011, 7: 102\u2013111.","journal-title":"Arch Med Sci"},{"key":"293_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 2014, 370: 311\u2013321.","journal-title":"N Engl J Med"},{"key":"293_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","volume":"69","author":"TE Golde","year":"2011","unstructured":"Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer\u2019s disease: the need for a paradigm shift. Neuron 2011, 69: 203\u2013213.","journal-title":"Neuron"},{"key":"293_CR40","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302: 2557\u20132564.","journal-title":"JAMA"},{"key":"293_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8","volume":"13","author":"A McCaddon","year":"1998","unstructured":"McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998, 13: 235\u2013239.","journal-title":"Int J Geriatr Psychiatry"},{"key":"293_CR42","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1016\/j.febslet.2006.04.088","volume":"580","author":"R Obeid","year":"2006","unstructured":"Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006, 580: 2994\u20133005.","journal-title":"FEBS Lett"},{"key":"293_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0955-2863(90)90070-2","volume":"1","author":"JD Finkelstein","year":"1990","unstructured":"Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990, 1: 228\u2013237.","journal-title":"J Nutr Biochem"},{"key":"293_CR44","doi-asserted-by":"publisher","first-page":"11477","DOI":"10.1523\/JNEUROSCI.2816-08.2008","volume":"28","author":"JM Sontag","year":"2008","unstructured":"Sontag JM, Nunbhakdi-Craig V, Montgomery L, Arning E, Bottiglieri T, Sontag E. Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation. J Neurosci 2008, 28: 11477\u201311487.","journal-title":"J Neurosci"},{"key":"293_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/JAD-2006-9403","volume":"9","author":"AM Troen","year":"2006","unstructured":"Troen AM, Shukitt-Hale B, Chao W-H, Albuquerque B, Smith DE, Selhub J, et al. The cognitive impact of nutritional homocysteinemia in Apolipoprotein-E deficient mice. J Alzheimers Dis 2006, 9: 381\u2013392.","journal-title":"J Alzheimers Dis"},{"key":"293_CR46","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaneurol.2018.0602","volume":"75","author":"SS Ong","year":"2018","unstructured":"Ong SS, Doraiswamy PM, Lad EM. Controversies and future directions of ocular biomarkers in Alzheimer disease. JAMA Neurol 2018, 75: 650\u2013651.","journal-title":"JAMA Neurol"},{"key":"293_CR47","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s00415-014-7374-z","volume":"261","author":"FJ Ascaso","year":"2014","unstructured":"Ascaso FJ, Cruz N, Modrego PJ, Lopez-Anton R, Santabarbara J, Pascual LF, et al. Retinal alterations in mild cognitive impairment and Alzheimer\u2019s disease: an optical coherence tomography study. J Neurol 2014, 261: 1522\u20131530.","journal-title":"J Neurol"},{"key":"293_CR48","doi-asserted-by":"crossref","unstructured":"Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight 2017, 2.","DOI":"10.1172\/jci.insight.93621"},{"key":"293_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bpa.12070","volume":"24","author":"CY Ho","year":"2014","unstructured":"Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer\u2019s and Parkinson\u2019s disease patients. Brain Pathol 2014, 24: 25\u201332.","journal-title":"Brain Pathol"},{"key":"293_CR50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000107152","volume":"1","author":"B Regland","year":"1990","unstructured":"Regland B, Abrahamsson L, Gottfries CG, Magnus E. Vitamin B12 analogues, homocysteine, methylmalonic acid, and transcobalamins in the study of vitamin B12 deficiency in primary degenerative dementia. Dement Geriatr Cogn Disord\u00a01990, 1: 272\u2013277.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"293_CR51","first-page":"2874","volume":"15","author":"XJ Shu","year":"2018","unstructured":"Shu XJ, Li ZF, Chang YW, Liu SY, Wang WH, Li X. Different doses of folic acid and vitamin B12 to treat rabbits with deep venous thrombosis and hyperhomocysteinemia. Exp Ther Med 2018, 15: 2874\u20132878.","journal-title":"Exp Ther Med"},{"key":"293_CR52","first-page":"11","volume":"7","author":"TG Guilliams","year":"2004","unstructured":"Guilliams TG. Homocysteine - a risk factor for vascular diseases: guidelines for the clinical practice. JANA\u00a02004, 7: 11\u201324.","journal-title":"JANA"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-018-0293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12264-018-0293-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-018-0293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T12:20:23Z","timestamp":1572006023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12264-018-0293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s12264-018-0293-8","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}